We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.41B
AUM Growth
-$2.89B
Cap. Flow
-$1.47B
Cap. Flow %
-27.24%
Top 10 Hldgs %
37.29%
Holding
165
New
19
Increased
15
Reduced
46
Closed
34

Top Buys

Rank Stock Value
1
LOGC
LogicBio Therapeutics, Inc. Common Stock
LOGC
+$78.1M
2
THOR
Synthorx, Inc. Common Stock
THOR
+$77.1M
3
CVS icon
CVS Health
CVS
+$59.3M
4
CELG
Celgene Corp
CELG
+$58.5M
5
GH icon
Guardant Health
GH
+$56.5M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$149M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$98.5M
3
BMY icon
Bristol-Myers Squibb
BMY
+$81.7M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81M
5
EW icon
Edwards Lifesciences
EW
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Financials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
76
Novo Nordisk
NVO
$228B
$15.2M 0.28%
660,000
– –
XTNT icon
77
Xtant Medical Holdings
XTNT
$59.1M
$14.8M 0.27%
9,207,012
– –
SYBX
78
DELISTED
Synlogic
SYBX
$14.2M 0.26%
135,333
– –
ACIU icon
79
AC Immune
ACIU
$231M
$13.6M 0.25%
1,440,000
– –
SCPH
80
DELISTED
scPharmaceuticals
SCPH
$12.8M 0.24%
3,409,865
– –
ALPN
81
DELISTED
Alpine Immune Sciences Inc
ALPN
$12.1M 0.22%
3,298,516
– –
VRNA
82
DELISTED
Verona Pharma
VRNA
$12.1M 0.22%
1,250,396
– –
VRCA icon
83
Verrica Pharmaceuticals
VRCA
$92.9M
$12.1M 0.22%
147,973
– –
THC icon
84
Tenet Healthcare
THC
$22.3B
$9.65M 0.18%
+562,785
New +$13.6M
NTRA icon
85
Natera
NTRA
$36.4B
$9.55M 0.18%
684,086
– –
HCA icon
86
HCA Healthcare
HCA
$90.8B
$9.45M 0.17%
75,900
– –
ALLK
87
DELISTED
Allakos
ALLK
$9.15M 0.17%
175,000
-25,000
-13% -$1.25M
NVTA
88
DELISTED
Invitae Corporation
NVTA
$9.12M 0.17%
824,549
-450,000
-35% -$5.83M
BSX icon
89
CALL
Boston Scientific
BSX
$69.1B
$8.84M 0.16%
+250,000
New +$9.07M
WHWK
90
Whitehawk Therapeutics
WHWK
$182M
$8.83M 0.16%
346,263
– –
ADAP
91
DELISTED
Adaptimmune Therapeutics
ADAP
$7.77M 0.14%
1,350,655
+684,062
+103% +$5.05M
DERM
92
DELISTED
Dermira, Inc.
DERM
$7.42M 0.14%
1,031,596
– –
NBRV
93
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$6.78M 0.13%
18,578
– –
ICPT
94
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$6.65M 0.12%
+66,000
New +$6.84M
BMRN icon
95
BioMarin Pharmaceuticals
BMRN
$12B
$6.51M 0.12%
76,500
– –
CELG
96
CALL
DELISTED
Celgene Corp
CELG
$6.41M 0.12%
+100,000
New +$7.38M
NVTR
97
DELISTED
Nuvectra Corporation Common Stock
NVTR
$5.72M 0.11%
350,000
– –
ATNX
98
DELISTED
Athenex, Inc. Common Stock
ATNX
$5.46M 0.1%
21,500
– –
NTLA icon
99
Intellia Therapeutics
NTLA
$1.49B
$5.15M 0.1%
377,600
-367,000
-49% -$6.82M
ICPT
100
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.82M 0.09%
+47,800
New +$4.95M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2018 Portfolio in Review

As of Q4 2018, OrbiMed held 165 positions worth $5.41B, down 35% from $8.3B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $1.47B in Q4 2018, closing 34 positions and reducing 46 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in LogicBio Therapeutics, Inc. Common Stock worth $67.3M.

  • OrbiMed's largest Q4 2018 buy was LogicBio Therapeutics, Inc. Common Stock: 6,466,783 shares worth $67.3M.
  • OrbiMed added most to Celgene Corp in Q4 2018, an estimated $58.5M increase.
  • OrbiMed's biggest Q4 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $98.5M.
  • OrbiMed fully exited Jazz Pharmaceuticals in Q4 2018, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 37% of its $5.41B portfolio in Q4 2018.
  • OrbiMed opened 19 new positions and closed 34 in Q4 2018.
  • OrbiMed's portfolio value fell 35% quarter-over-quarter to $5.41B.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.